Evaxion AS ADR EVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.02
- Day Range
- $2.99–3.04
- 52-Week Range
- $2.50–11.94
- Bid/Ask
- $2.32 / $3.79
- Shares Outstanding
- 8.34M
- Market Cap
- $25.27M
- Volume/Avg
- 22,014 / 29,916
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 46
- Website
- https://www.evaxion.ai
Valuation
|
Metric
|
EVAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.86 |
Price/Sales | 2.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVAX
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | −3.80 |
Quick Ratio
EVAX
Profitability
|
Metric
|
EVAX
|
|---|---|
Return on Assets (Normalized) | −37.69% |
Return on Equity (Normalized) | −204.60% |
Return on Invested Capital (Normalized) | −53.77% |
Return on Assets
EVAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t#$JXN | LOCK|>&&m | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|NLDYBV | LOCK|>T<g | $69B | |||
| argenx SE ADR
ARGX
| LOCK|?cV?b^x | LOCK|^C& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#!!%QK# | LOCK|!#yM | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r%v&JG | LOCK|^TQ | $36B | |||
| Moderna Inc
MRNA
| LOCK|$Kb>^n | LOCK|gV | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|y>tWW>$S | LOCK|>H>q | $25B | |||
| Incyte Corp
INCY
| LOCK|dp>nsj | LOCK|r^J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|STp!?<% | LOCK|!c> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&$L!r% | LOCK|N^ | $16B |
United States